Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 7 October 2020, 13:00 HKT/SGT
Share:
    

Source: The Office of Terence Loh
Terence Loh and Nelson Loh, Co-Founders of Novena Global Healthcare, Announce Legal Separation of Business Interests

SINGAPORE, Oct 7, 2020 - (ACN Newswire) - Mr Terence Loh and Mr Nelson Loh, directors and co-founders of the Novena Global Healthcare group of companies, have entered into an agreement to legally separate all their businesses interests, Mr Terence Loh announced today.

Terence Loh, Co-founder of Novena Global Healthcare Group

Under a Separation Agreement entered into between the two cousins and former business partners on 6 October 2020,

1. Terence Loh will transfer all the shares he owns in Singapore-registered Bellagraph Nova Pte. Ltd. ("BNG (SG)") to Nelson Loh for one Singapore dollar (S$1). Thereafter, Terence Loh will resign as director of BNG (SG).
2. Nelson Loh will transfer all shares he owns in three corporate entities to Terence Loh for one Singapore dollar (S$1). Thereafter, Nelson Loh will resign as director of these three entities, namely:
- Singapore-registered Dorr Global Healthcare International Pte. Ltd.;
- Singapore-registered Rock Star Advisors Pte. Ltd.; and
- Cayman Islands-registered Novena Global Healthcare Group and all subsidiaries.

Terence Loh and Nelson Loh have agreed to complete the share transfers and resignations of directorships by 5 November 2020, provided that there are no unforeseeable difficulties. Both parties will entire into a written agreement if an extension is required.

The Separation Agreement follows recent media coverage surrounding the two former business partners, as well as police investigations into complaints by auditors Ernst & Young of forgery of financial statements.

Under the agreement, should Terence Loh discover after 6 October 2020 that he is jointly a shareholder and/or director of any other company other than the four entities cited, both he and Nelson Loh will do all that is necessary to effect a termination of such shareholding and/or directorship.

With reference to media statements relating to proposed corporate actions of the Bellagraph Nova Group, the Separation Agreement cites Nelson Loh's acknowledgement that Terence Loh, though a Director in BNG (SG), was not involved in any business decisions within BNG (SG).

Ms Evangeline Shen, speaking on behalf of the "Bellagraph Nova Group", has been quoted by the international media earlier this month that the latter was still pursuing a takeover bid of the Newcastle United Football Club, which competes in the Premier League in the United Kingdom.

"Nelson acknowledges and agrees that although Terence is a director of BNG (SG), his views and approval as a director of BNG (SG) were not sought prior to Evangeline Shen commenting to the media that the Bellagraph Nova Group was still pursuing a takeover bid in relation to Newcastle United Football Club," the Separation Agreement stated.

Nelson Loh also "acknowledges and agrees that he remains liable on all guarantees that he executed despite the separation of interests" as set out in the Separation Agreement.

Terence Loh commented: "This is a mutually agreed and legally binding document which clearly separates the business interests that Nelson and I have been involved in since 2008. We have gone through many challenges together and the time has come now for each of us to chart our separate careers and pursuits."

"This agreement provides clarity for me to resolve legal and corporate issues of the businesses transferred to me. In relation to the alleged forgery of the accounts of Novena Global Healthcare Group, I unequivocally state that I was not involved in the forgery. I have remained in Singapore and continue to be available to assist the Commercial Affairs Department ("CAD"). I do not wish to comment on the press release issued earlier today by the Bellagraph Nova Group. My focus is to do my best to preserve and enhance value for stakeholders in the corporate entities for which I am a director. The role that others have played in the current difficulties will become, in due course, clear," Terence Loh added.

Media Relations Contact:
WeR1 Consultants Pte Ltd
Whatsapp (text only): +65 9748 0688
Email: mediacontactTL@wer1.net


Topic: Press release summary
Source: The Office of Terence Loh

Sectors: Daily Finance, Daily News, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership  
Monday, December 15, 2025 7:30:00 AM
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion  
Friday, December 12, 2025 10:15:00 PM
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten  
Dec 12, 2025 14:35 HKT/SGT
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition  
Friday, December 12, 2025 10:00:00 AM
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China  
Dec 11, 2025 20:00 HKT/SGT
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing  
Dec 11, 2025 18:09 HKT/SGT
Nasdaq Verafin Joins Global Anti-Scam Alliance  
Dec 11, 2025 14:21 HKT/SGT
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards  
Dec 11, 2025 12:54 HKT/SGT
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating  
Dec 11, 2025 08:20 HKT/SGT
Indonesian Government's Swift Response in Recovering Flood-hit Sumatra  
Dec 10, 2025 23:30 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: